Published in Gene Therapy Weekly, March 3rd, 1997
DCs are extremely potent antigen presenting cells (APCs). They have the capacity to acquire and process antigens, to migrate to lymphoid organs, and to stimulate antigen-specific T cells to proliferate. Only recently have methods been developed which make it possible to culture large numbers of DCs from the adherent fraction of peripheral blood mononuclear cells (PBMCs) (S.M. Kiertscher et al., J. Leukoc. Biol., 1996;59:208-18).
Jill F. Arthur and colleagues from the University of California hypothesized that genetic engineering of DCs to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.